Brainomix 360 Triage Stroke

K232496

Brainomix Limited · cleared 2023-11-21 · product code QAS · Radiology

Premarket evidence — what FDA accepted

Device typesamd
source quote (p.6)
Brainomix 360 Triage Stroke is a radiological computer aided triage and notification software package compliant with the DICOM standard and running on an off-the-shelf physical or virtual server.
Algorithmmachine learning algorithms that uses advanced non adaptive imaging algorithms, artificial intelligence, and large data analytics
source quote (p.6)
Brainomix 360 Triage Stroke is a stand-alone software device which uses machine learning algorithms that uses advanced non adaptive imaging algorithms, artificial intelligence, and large data analytics to automatically identify suspected LVO and ICH on non-contrast CT (NCCT) imaging acquired from adult patients in the acute setting, within 24 hours of the onset of the acute symptoms, or where this is unclear, since last known well (LKW) time.
Adaptive (vs locked)No
source quote (p.6)
machine learning algorithms that uses advanced non adaptive imaging algorithms
PCCPFDA source did not state this
Cybersecurity addressedFDA source did not state this

Validation studies (2)

Retrospective clinical

n=267 cases

endpoints: assessing the performance of Brainomix 360 Triage Stroke in identifying NCCT head images containing intracranial hemorrhage (ICH) or large vessel occlusion (LVO) findings

standards: 21 CFR Part 820.30, EN ISO 14971:2019, IEC 62304:2015

Reader study (MRMC)

n=227 cases

endpoints: compare NCCT LVO sensitivity of the device to that of radiologists; expert non-inferiority; non-expert superiority

standards: 21 CFR Part 820.30, EN ISO 14971:2019, IEC 62304:2015

Reported performance (10 observations)

sensitivity0.925CI 95% CI: 80.97-98.36%
source quote (p.10)
Specifically, ICH performance was observed at 92.5% sensitivity (95% CI: 80.97-98.36%)
specificity0.8722CI CI: 82.39-91.18%
source quote (p.10)
and 87.22% specificity (CI: 82.39-91.18%).
sensitivityas written: “NCCT LVO Sensitivity0.6875CI CI: 59.71-76.90%
source quote (p.10)
NCCT LVO performance was observed at 68.75% sensitivity (CI: 59.71-76.90%)
specificityas written: “NCCT LVO Specificity0.8957CI CI: 82.92-94.36%
source quote (p.10)
and 89.57% specificity (CI: 82.92-94.36%).
sensitivityas written: “Reader Study Sensitivity (all readers)0.4794CI CI: 37.91-57.97%
source quote (p.10)
Triage Stroke passed both conditions, with a sensitivity for all readers (experts and non-experts) of 47.94% (CI: 37.91-57.97%).
sensitivityas written: “Difference between device and all readers sensitivity0.2052CI CI: 8.26-32.78%
source quote (p.10)
The difference between the device's sensitivity and that of all readers was 20.52% (CI: 8.26-32.78%).
sensitivityas written: “Reader Study Sensitivity (non-experts)0.4718CI CI: 33.62-60.75%
source quote (p.10)
The general radiologists (non-experts) performed with a sensitivity of 47.18% (CI: 33.62-60.75%).
sensitivityas written: “Difference between device and non-expert sensitivity0.2128CI CI: 5.84-36.72%
source quote (p.10)
The difference between the device and non-expert sensitivity was 21.28% (CI: 5.84-36.72%).
time_to_resultas written: “Minimum expected time-to-notification62
source quote (p.10)
The results were a minimum expected time-to-notification of 62 seconds
time_to_resultas written: “Maximum expected time-to-notification134
source quote (p.10)
and a maximum of 134 seconds.

Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.

Predicate network

Postmarket — what happened after clearance

0
recalls in product code, 24mo
0
MAUDE reports in code, 12mo
vs code's own 3-yr baseline
1
drift signals on this device
  • re_clearance

    The FDA AI/ML device list shows a newer 510(k) K251983 (decision 2025-08-26) from Brainomix Limited for a matching device line ("Brainomix 360 Triage Stroke") — a new clearance for the same line is a change event.

    first seen 2026-07-08 · k_number:K251983

Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.

Reimbursement — how devices like this got paid

Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).

RIGOR™ Precedent · public FDA/CMS data · descriptive decision-support, not regulatory or reimbursement advice. Share this page: radar.healthai.com/precedent/device/K232496